Objective-Circulating angiogenic cells (CACs), also termed endothelial progenitor cells, play an integral role in vascular repair and are functionally impaired in coronary artery disease (CAD). The role of nitric oxide (NO) in CAC function is poorly understood. We hypothesized that CAC migration toward angiogenic signals is modulated by both NO synthase (NOS) expression and functional response to NO. Methods and Results-Similar to endothelial cells, CAC chemotaxis to vascular endothelial growth factor (VEGF) was blocked by inhibition of NOS, phosphatidylinositol 3-kinase, or guanylyl cyclase or by treatment with an NO scavenger. Addition of an NO donor (S-nitroso-N-acetylpenicillamine) and the NOS substrate L-arginine increased random cell migration (chemokinesis) and enhanced VEGF-dependent chemotaxis. Healthy CACs expressed endothelial NOS, but endothelial NOS was not detected in CAD patient CACs. Both chemokinesis and chemotaxis to VEGF of patient CACs were decreased compared with healthy CACs but were restored to healthy values by S-nitroso-N-acetylpenicillamine.
N O is an important signaling molecule in vascular biology. 1 Physiologically, many integral functions of the vascular endothelium are modulated by endothelial nitric oxide synthase (eNOS)-derived NO, including the inhibition of platelet and leukocyte adhesion, smooth muscle relaxation, and proliferation. Newer literature shows that NO not only acts in paracrine manner but may also exert systemic effects via reversible formation of more stable storage forms, including nitrite and nitoso-adducts. The disruption of this pathway in endothelial cells is associated with chronic vascular disease. 2 Risk factors appear to selectively damage the vascular endothelium, leading to a dysfunctional, maladaptive endothelial phenotype. 3, 4 Studies suggest that eNOS activity and expression as well as circulating NO storage forms in blood are progressively decreased with cardiovascular risk factors including aging, hypertension, hypercholesterolemia, diabetes, and smoking and cigarette smoke exposure. 2, [5] [6] [7] Over time, chronic endothelial dysfunction leads to intimal hyperplasia and enhanced plaque formation in predisposed areas of the vascular tree. Notably, the functional capacity of the vascular endothelium not only depends on the degree of damage but also on the presence and status of repair systems, including circulating angiogenic cells (CACs). 8 Vascular repair involves not only local migration and proliferation of mature endothelial cells but also angiogenic cells that circulate in blood and the recruitment of the latter cells to sites of injury. Literature from the last 10 years suggests that circulating proangiogenic blood cells can enhance angiogenesis and the replacement of vascular endothelium. 8 -10 These cells were initially termed endothelial progenitor cells because of their phenotypic similarities to mature endothelial cells, including kinase insert domain receptor, eNOS, and platelet endothelial cell adhesion molecule (CD31), but also to stem cells (CD34 and CD133) and myeloid cells (CD14 and CD45). Newer literature suggests that these early outgrowth angiogenic cells temporarily aid endothelial repair, rather than developing into mature endothelial cells, in contrast to late outgrowth endothelial colonyforming cells, which can form endothelial tubes and monolayers. 11, 12 Therefore, these cells are herein referred to as CACs rather than early endothelial progenitor cells. Clinical and experimental studies show that the reparative and therapeutic potency of CACs is determined by their functional status, which, in turn, are characterized by migratory capacity toward chemotactic signals, such as vascular endothelial growth factor (VEGF). 13, 14 Several studies suggest that cardiovascular disease not only may be caused by endothelial damage but also may cause or be caused by CAC dysfunction. The number or function of these cells is reduced with aging, 6 hypertension, diabetes, 15 smoking, 16 and environmental smoke exposure. 17 CAC dysfunction was shown to limit the therapeutic potency of these cells when transplanted. 13 It is conceivable that the functional capacities of CACs in patients may also be affected by the pathomechanisms that impair endothelial cell dysfunction, including decreased NO production and bioavailability, further facilitating vascular disease progression. 18 The role of NO activity in fundamental functional CAC capacities is not well studied. We hypothesized that CAC migration is modulated by NO and that CAC dysfunction in coronary artery disease (CAD) patients is a result of reduced NO bioavailability in blood or decreased NOS expression.
We first characterized the chemotactic response of CACs and compared the results with human umbilical vein endothelial cells (HUVECs), serving as a standard endothelial cell system. We then studied the effect of the NO donor S-nitroso-N-acetylpenicillamine (SNAP) on migration of CACs and HUVECs. Finally, we measured eNOS expression and migratory responses in ex vivo-differentiated CACs isolated from CAD patients, who were shown to experience endothelial dysfunction with impaired NO bioavailablity, and compared them with results from young, healthy volunteers.
Methods

Study Subjects
CACs were isolated from 10 young, healthy subjects without cardiovascular risk factors (hypertension, diabetes mellitus, smoking, and hypercholesterolemia, which are associated with impaired number and function of CACs), and with normal endothelial function (as measured by flow-mediated dilation [FMD] of the brachial artery of greater than 6%). 2, 6, 19 (See Supplemental Table I , available online at http://atvb.ahajournals.org, for characteristics.) We also isolated CACs from 10 patients with angiographically documented CAD as defined by Ͼ70% stenosis of at least 1 coronary artery on optimal medical therapy according to current secondary prevention guidelines 20 and endothelial dysfunction with FMD Ͻ5%. The characterization of CACs, including mechanistic experiments, was performed in CACs isolated from the healthy subjects. The protocol was approved by the University of California, San Francisco, Committee on Human Research, and volunteers gave written informed consent.
Cell Culture and Characterization of Blood-Derived CACs
CACs were differentiated ex vivo from peripheral blood mononuclear cells as previously described (see supplemental material for more detailed characterization protocols). 11, 21 CACs were isolated from mononuclear cells as adherent cells on fibronectin-coated dishes after 7 days. Culture was preceded by 1 day of preplating to remove platelets and shed endothelial cells. eNOS protein was quantitated in cell lysates of CACs at day 7 and VEGF in cell medium of adherent and nonadherent cells using commercially available ELISA kits following the manufacturer's protocol (Quantikine, R&D Systems). Marker expression (CD45, CXCR4, CD31, kinase insert domain receptor, CD11b, CD14, CD3, CD34, CD133) of day 7 cells was determined by flow cytometry.
Pooled HUVECs were purchased from Cambrex (Walkersville, Md), cultured in EBM-2 (supplemented with Singlequots 5% FBS) and used no later than passage 3.
Chemotaxis and Chemokinesis Assay
Cell migration was quantified by a transwell chemotaxis assay using a modified Boyden chamber. 13, 22, 23 Migration of both CACs and HUVECs was measured as follows: cells (2ϫ10 4 ) were plated in EBM-2 medium (0.5% BSA, without other supplements, containing 63 mg/L L-arginine) in the upper of 2 chambers divided by a membrane with 8-m pores (Corning Transwell). We tested the chemotactic properties of the following chemoattractants in only the lower chamber: vascular endothelial growth factor (VEGF, Sigma), stromal cell-derived factor (SDF-1␣; Sigma), and pleiotrophin (PTN; Sigma) at 10 to 500 ng/mL; and monocyte chemoattractant protein 1 (Sigma), sphingosine-1-phosphate (Sigma), and interleukin 6 (Sigma) at 10 to 100 ng/mL. The following were added to both the upper and lower chamber: the NOS substrate L-arginine (100 mol/L),
quinoxalin-1-one (ODQ; 100 mol/L), PI3K inhibitor wortmannin (WM; 100 nmol/L), and NO donor SNAP (Sigma) at 1 nmol/L to 10 mol/L. The number of migrated cells was determined on 5 random ϫ100 optical fields per membrane. To distinguish chemokinetic from chemotactic properties of VEGF and SNAP, both substances were added to upper and lower chambers in a checkerboard fashion.
Cell Proliferation and Apoptosis Assays
5-Bromodeoxyuridine incorporation assays were performed in 96well dishes following the manufacturer's protocol (Cell Proliferation BrdU Assay, Roche). Apoptosis assays were performed with fluorescence-activated cell sorting essentially as described in the manufacturer's protocol (Guava, Hayward, Calif). cGMP levels were measured in 10 5 cells under baseline unstimulated conditions and after incubation with SNAP at 1 mol/L for 30 minutes using an ELISA kit following the manufacturer's protocol (GE Healthcare).
FMD
Endothelium-dependent dilation of the brachial artery was measured by ultrasound (Sonosite Micromax, Bothell, Wash) in combination with an automated analysis system (Brachial Analyzer, Medical Imaging Applications, Iowa City, Iowa) as described (see supplemental material for details). 17
Plasma Nitrite Level
The plasma nitrite levels, representing a sensitive readout of NOS activity, were measured as recently described using gas-phase chemiluminescence (see supplemental material for details). 24 
Statistical Analyses
Data are presented as meanϮstandard error of the mean. Group differences were calculated with repeated measurements ANOVA and consecutive post hoc test. Probability values of less than 0.05 were regarded as significant. Correlations were by the Pearson r. All experiments were performed in triplicate.
Results
CAC Characterization
During culture, mononuclear cells gave rise to adherent cells progressively expressing eNOS and releasing VEGF ( Figure  1 ). At day 7, the majority of adherent cells expressed markers consistent with the early proangiogenic hematopoietic endothelial progenitor cell type as described in the literature, whereas nonadherent cells, which were not further studied herein, were mainly consistent with lymphocytes. 11, 25, 26 CACs migrated dose-dependently to a number of chemokines including VEGF, SDF-1␣, PTN, 23 sphingosine-1-phosphate, and monocyte chemoattractant protein 1 but not to interleukin 6 at the concentrations tested ( Figure 1D ). Of the investigated chemokines, SDF-1␣ exerted the strongest migratory response (SDF-1␣ϾVEGFϭPTNϾmonocyte chemoattractant protein 1ϭsphingosine-1-phosphate).
Mechanisms of CAC Chemotaxis: Similarity With Endothelial Cells (HUVECs)
Further experiments showed that random cell movement in the presence of VEGF (50 ng/mL) in the upper and lower chambers (that is, no gradient) did not lead to significantly more cells on the lower side of the membrane compared with the negative control lacking VEGF (Figure 2A and 2B ). This confirms that VEGF does not merely induce a significant chemokinetic response but stimulates specific chemotactic responses in CACs and HUVECs. 23 To gain mechanistic insight into chemotaxis of CACs, we performed inhibitor studies to attempt to block the VEGFinduced chemotaxis ( Figure 2C and 2D). Chemotaxis toward VEGF at 50 ng/mL was inhibited in the presence of a NOS inhibitor (L-NNA), an NO scavenger (PTIO), a phosphatidylinositol 3-kinase inhibitor (WM), and a guanylyl cyclase inhibitor (ODQ). Nondirectional cell movement, without addition of chemokines, remained unaffected by these inhibitors, suggesting that the observed lack of chemotaxis is due to specific inhibition of the pathways in question and cannot be explained by unspecific cell toxicity or globally disabled cell motility. Furthermore, our experiments show that the mechanisms involved in CAC chemotaxis are similar in HUVECs. Interestingly, L-arginine in the upper and lower chambers (no gradient) not only increased chemotaxis toward the VEGF gradient but enhanced chemokinesis.
NO Donor Induces Chemokinesis and Enhances Chemotaxis
To test how NO itself affects CAC motility and whether CACs follow a gradient of NO, we performed migration assays with the NO donor SNAP ( Figure 3 ). As opposed to VEGF, SNAP induced a strong increase in random cell movement (chemokinesis). However, the number of migrated cells when SNAP (1 mol/L; measured NO concentration in medium, 2.7 and 0.8 nmol/L at 0 and 3 hours, respectively) was present in both the upper and lower chambers was greater than when SNAP was present only in the lower chamber, suggesting that NO is a stronger inductor of chemokinesis than chemotaxis. Dose-dependent chemokinesis at 0.01 to 50 mol/L showed a maximum at 1 mol/L (28Ϯ3 cells/ high-power field). Directional cell movement toward a VEGF gradient was also present at these SNAP concentrations. The highest absolute number of migrated cells was observed with a VEGF gradient (50 ng/mL) in the presence of SNAP at 1 mol/L (34Ϯ4 cells/high-power field). These findings illustrate that SNAP-mediated chemokinesis acts synergisti- cally with VEGF-induced chemotaxis to enhance the number of net migrated cells, suggesting that exogenous NO facilitated directional cell movement to a chemokine stimulus. Addition of ODQ and PTIO but not L-NNA inhibited the chemokinetic SNAP (1 mol/L) response, suggesting guanylate cyclase dependence, NO specificity, and NOS independence. This shows that both CACs and HUVECs similarly distribute faster in the presence of NO but are still responsive toward chemotactic stimuli.
In addition to its effects on cell migration, SNAP dosedependently inhibited both VEGF-induced and spontaneous CAC proliferation (Figure 4) . Conversely, inhibition of NOS by L-NNA stimulated proliferation to a degree similar to VEGF, suggesting opposite effects of VEGF and NO with respect to proliferation, as previously shown. 23 VEGFinduced proliferation was inhibited by WM, suggesting dependence of this effect on phosphatidylinositol 3-kinase but not NOS.
SNAP also dose-dependently inhibited camptothecininduced apoptosis of CACs (Figure 4 ). Early apoptosis was identified by annexin V binding (AnnV ϩ ) along with 7-AAD exclusion (7-AAD Ϫ ), showing that the cell membrane was intact. AnnV ϩ , along with 7-AAD uptake (ie, disrupted membrane), identified late apoptosis. Vital cells were identified as being negative for AnnV ϩ and 7-AAD. Camptothecin dose-dependently induced apoptosis in CACs. Maximal apoptosis of CACs was achieved with Ͼ10 mol/L camptothecin at 3 hours (40% early apoptosis AnnV ϩ /7-AAD; 20% late apoptosis AnnV ϩ /7-AAD ϩ ). Coincubation of SNAP at 0.1 to 100 mol/L led to dose-dependent inhibition of camptothecin-induced apoptosis at 50 mol/L, with significantly higher numbers of vital cells (AnnV Ϫ /7-AAD Ϫ ). Maximal effects were observed at 1 mol/L SNAP. The degree of apoptosis inhibition was similar to that induced by VEGF (50 ng/mL), which is known to inhibit apoptosis. Similar results were obtained when apoptosis was induced by staurosporin (data not shown).
Impaired CAC Migration and NOS Expression in CAD Patients
To show the clinical relevance of these findings to human cardiovascular disease, we measured CAC migration as a readout of therapeutic potency and quantitated eNOS protein in CACs from older CAD patients compared with those from younger, healthy subjects (age, 56Ϯ3 versus 30Ϯ2 years; PϽ0.001). Supplemental Table I summarizes the clinical baseline characteristics. Flow-mediated vasodilation (FMD; 4.7Ϯ0.7 versus 6.8Ϯ0.3%, PϽ0.001, Figure 5 ) and plasma nitrite (38Ϯ3 versus 60Ϯ3 nmol/L, PϽ0.001) were significantly lower in the patients, demonstrating endothelial dysfunction and impaired systemic NO bioavailability in these patients despite optimal medical therapy including statins.
In vitro assays showed that in CAD both unstimulated random CAC movement and chemotaxis toward VEGF (5Ϯ3 and 7Ϯ4 cells/high-power field, respectively) were significantly impaired compared with healthy subjects (11Ϯ2 and 26Ϯ4 cells/high-power field, each PϽ0.001; Figure 5 ). Importantly, eNOS levels were also significantly reduced (below the detection limit of the assay) in older CAD patients compared with healthy volunteers, offering a feasible explanation for the decreased functional capacity of these patients' CACs. SNAP added to both chambers at 0 to 1 mol/L led to a similar dose-dependent chemokinetic migratory response in both groups and enhanced chemotaxis to VEGF (healthy nϭ10, CAD nϭ5, because of insufficient number of cells from 5 of the patients). In the presence of SNAP at Ͼ0.1 mol/L, the migratory response was not significantly different between healthy and CAD patients. Whereas baseline intracellular cGMP levels were significantly lower in CAD, there was no significant difference between healthy and CAD after incubation with SNAP (1 mol/L). No significant differences were seen in CD45 (98Ϯ2%, 97Ϯ1%) and CD31 (26Ϯ4%, 34Ϯ9%) expression by fluorescence-activated cell sorting, and inducible NOS mRNA was not detected in either kind of cell (data not shown). This suggests that response to exogenous NO was preserved in CAD patients despite a reduction in NOS-dependent response to endogenous NO.
Discussion
Our data show that both endogenous NOS activity and exogenous NO modulate CAC motility. NOS activity is required for chemotactic migration of CACs to angiogenic chemokines, whereas exogenous NO induces chemokinesis, enhancing directional chemotaxis toward VEGF, without directly acting as a chemoattractant itself. Notably, the effects of the NO donor SNAP and NOS on the CACs were qualitatively similar to their effects on HUVECs, despite the presumption that these early proangiogenic CACs do not function as direct endothelial precursors. We show clinical relevance in that CAC migration in CAD patients is limited by decreased endogenous NOS activity because of impaired expression rather than impaired response to exogenous NO.
NOS plays an important regulatory role in vascular biology, and defective endothelial NO synthesis may limit angiogenesis in patients with endothelial dysfunction. 27 An impairment of the endogenous NO signaling in endothelium is coupled with the inability to produce an angiogenic response to VEGF. 28, 29 The effects of NO on CACs, which are important cells for endothelial repair, are not well understood. We describe here how the presence or absence of NO affects CAC motility. Corroborating previous studies, 17, 23, 30 we demonstrate that CACs NOS-dependently migrate to a number of chemokines. This supports the notion that NOS represents an integral pathway for cell migration. We have recently shown that CACs migrate to a gradient of PTN in a manner that is dependent on NOS, cGMP, NO, and PI3K. 23 Similarly, it was previously shown by others that SDF-1␣ induces CAC migration in an eNOS-, Akt-, and PI3K -dependent manner. 30 We show here that the migration to VEGF involves the same pathways as migration to PTN and SDF-1␣. This is important because a number of risk factors promoting arteriosclerosis and poor tissue regeneration, including smoking, aging, diabetes, hypertension, and hypercholesterolemia, have been shown to also inhibit NO production. 2, 17 These factors may mediate part of their vascular pathology by affecting vascular maintenance exerted by lowered NOS activity potentially via oxidative stress not only in endothelial cells but also in CACs, leading to dysfunction of these cells. This is supported by several studies in animal models and human clinical studies. In a recent clinical report, we have shown that passive smoke may decrease CAC migration by blocking NO production. 17 Animal hindlimb ischemia experiments have revealed that angiogenesis is impaired in eNOS Ϫ/Ϫ mice and that the eNOS substrate L-arginine can enhance angiogenesis in rabbits. 27 Another study suggests that diabetes may impair reendothelialization by impaired CAC function due to decreased eNOS expression. 31 More recently, it was shown in diabetic rats and patients that diabetes may impair CAC functions by uncoupling eNOS. 15 Taken together, our data suggest that dysfunctional CAC migration in CAD patients may be due to lower eNOS expression rather than impaired response to exogenous NO in CACs. To our knowledge, this is the first report to show the effect of exogenous NO on CAC migratory function. We show that an NO donor induces chemokinesis. It is important to note that this does not impair the CACs' capacity to sense chemoattractant gradients and follow them, but actually significantly also increases the net number of migrated cells at the site of higher chemokine concentration ( Figure 6 ). This is in agreement with previously published results by others showing that HUVECs cGMP-dependently migrate toward a gradient of NO using different NO donors, 1,1-diethyl-2-hydroxy-2-nitroso-hydrazine and 2,2Ј-(Hydroxynitrosohydrazono)bis-ethanimine, which have a longer half-life than SNAP. 32 To methodically exclude the possibility that SNAP merely increases cell proliferation at the lower side of the membrane, we performed proliferation assays showing that NO in fact decreases proliferation. 33 Corroborating results by others, we show that SNAP also decreased apoptosis. 34 In the context of the present study, we cannot exclude the possibility that NO increases survival of CACs and may thereby explain part of the migration results, potentially contributing to more cells recovered at the lower side of the membrane. Mechanistically, both CACs and HUVECs release NO, and chemotaxis of both cell types is enhanced by NO-related chemokinesis. This suggests that NO may serve as a signal coordinating and potentially stimulating endothelial and proangiogenic cell interactions. NO and chemokines released by proangiogenic CACs that have homed to sites of injury may further attract new cells in a positive feedback loop by facilitating chemotaxis and chemokinesis. Once cells reach each other, higher NO levels may enhance adhesion (Heiss et al, unpublished results, 2007) and inhibit proliferation and apoptosis while facilitating even dispersal via chemokinesis of CACs and endothelial cells. As the observed effects were dose dependent, the effect may likely differ between sites with different NO levels, such as inflammation with expression of high-output inducible NOS (micromolar range) or vascular endothelium (low nanomolar range). Furthermore, these results may have clinical importance in disease states with lowered NO bioavailability, eg, decreased levels of plasma S-nitrosothiols or nitrite, which represent physiological NO donors with cardiovascular risk factors. 2, 24, 35, 36 Our data further support the concept that the NOS/NO pathway is a strong modulator of CAC functions, as it is in endothelial cells. CAC functions are likely to be affected both by factors that impair this pathway of endothelial cells in patients with cardiovascular disease in vivo and by reduced NO bioavailability. 2 Figure 6 . Schematic to illustrate the proposed additive effects of directional (chemotaxis) and nondirectional (chemokinesis) random cell movement.
